Australian biotech firm Actinogen Medical has developed Xanamem, a once-daily pill targeting cortisol production in the brain, showing promise in slowing Alzheimer's progression. Dubbed a potential "holy grail" in treatment, Xanamem aims to address cognitive decline by modulating stress hormone levels. Clinical trials are underway to evaluate its efficacy and safety.

‍